Husam Abdel-Qadir1, Idan Roifman1, Harindra C Wijeysundera1. 1. Institute for Clinical Evaluative Sciences (Abdel-Qadir, Roifman, Wijeysundera); Schulich Heart Program and the Sunnybrook Research Institute (Roifman, Wijeysundera); Institute for Health Policy, Management and Evaluation (Abdel-Qadir, Roifman, Wijeysundera), University of Toronto; Women's College Hospital (Abdel-Qadir), Toronto, Ont.
Abstract
BACKGROUND: The use of prasugrel or ticagrelor as part of dual antiplatelet therapy with acetylsalicylic acid after acute coronary syndrome (ACS) improves clinical outcomes relative to clopidogrel. The relative cost-effectiveness of these agents are unknown. We conducted an economic analysis evaluating 12 months of treatment with clopidogrel, prasugrel or ticagrelor after ACS. METHODS: We developed a fully probabilistic Markov cohort decision-analytic model using a lifetime horizon, from the perspective of the Ontario Ministry of Health and Long-Term Care. The model incorporated risks of death, recurrent ACS, heart failure, major bleeding and other adverse effects of treatment. Data on probabilities and utilities were obtained from the published literature where available. The primary outcome was quality-adjusted life-years (QALYs). RESULTS: Treatment with clopidogrel was associated with the lowest effectiveness (7.41 QALYs, 95% confidence interval [CI] 1.05-14.79) and the lowest cost ($39 601, 95% CI $8434-$111 186). Ticagrelor treatment had an effectiveness of 7.50 QALYs (95% CI 1.13-14.84) at a cost of $40 649 (95% CI $9327-$111 881). The incremental cost-effectiveness ratio (ICER) for ticagrelor relative to clopidogrel was $12 205 per QALY gained. Prasugrel had an ICER of $57 630 per QALY gained relative to clopidogrel. Ticagrelor was the preferred option in 90% of simulations at a willingness-to-pay threshold of $50 000 per QALY gained. INTERPRETATION: Ticagrelor was the most cost-effective agent when used as part of dual antiplatelet therapy after ACS. This conclusion was robust to wide variations in model parameters.
BACKGROUND: The use of prasugrel or ticagrelor as part of dual antiplatelet therapy with acetylsalicylic acid after acute coronary syndrome (ACS) improves clinical outcomes relative to clopidogrel. The relative cost-effectiveness of these agents are unknown. We conducted an economic analysis evaluating 12 months of treatment with clopidogrel, prasugrel or ticagrelor after ACS. METHODS: We developed a fully probabilistic Markov cohort decision-analytic model using a lifetime horizon, from the perspective of the Ontario Ministry of Health and Long-Term Care. The model incorporated risks of death, recurrent ACS, heart failure, major bleeding and other adverse effects of treatment. Data on probabilities and utilities were obtained from the published literature where available. The primary outcome was quality-adjusted life-years (QALYs). RESULTS: Treatment with clopidogrel was associated with the lowest effectiveness (7.41 QALYs, 95% confidence interval [CI] 1.05-14.79) and the lowest cost ($39 601, 95% CI $8434-$111 186). Ticagrelor treatment had an effectiveness of 7.50 QALYs (95% CI 1.13-14.84) at a cost of $40 649 (95% CI $9327-$111 881). The incremental cost-effectiveness ratio (ICER) for ticagrelor relative to clopidogrel was $12 205 per QALY gained. Prasugrel had an ICER of $57 630 per QALY gained relative to clopidogrel. Ticagrelor was the preferred option in 90% of simulations at a willingness-to-pay threshold of $50 000 per QALY gained. INTERPRETATION:Ticagrelor was the most cost-effective agent when used as part of dual antiplatelet therapy after ACS. This conclusion was robust to wide variations in model parameters.
Authors: John J V McMurray; Fredrik L Andersson; Simon Stewart; Klas Svensson; Alain Cohen Solal; Rainer Dietz; Johan Vanhaecke; Dirk J van Veldhuisen; Jan Ostergren; Christopher B Granger; Salim Yusuf; Marc A Pfeffer; Karl Swedberg Journal: Eur Heart J Date: 2006-06 Impact factor: 29.983
Authors: Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith Journal: Circulation Date: 2011-03-28 Impact factor: 29.690
Authors: Damian J Kelly; Tony Gershlick; Bernhard Witzenbichler; Giulio Guagliumi; Martin Fahy; George Dangas; Roxana Mehran; Gregg W Stone Journal: Am Heart J Date: 2011-10 Impact factor: 4.749
Authors: Craig I Coleman; Andrew D Straznitskas; Diana M Sobieraj; Jeffrey Kluger; Moise W Anglade Journal: Am J Cardiol Date: 2012-01-03 Impact factor: 2.778
Authors: Christopher P Cannon; Steen Husted; Robert A Harrington; Benjamin M Scirica; Håkan Emanuelsson; Gary Peters; Robert F Storey Journal: J Am Coll Cardiol Date: 2007-10-23 Impact factor: 24.094
Authors: Kathryn W Holmes; Cheryl L Maslen; Mark Kindem; Barbara L Kroner; Howard K Song; William Ravekes; H C Dietz; Jonathan W Weinsaft; Mary J Roman; Richard B Devereux; Reed E Pyeritz; Joseph Bavaria; Karianna Milewski; Dianna Milewicz; Scott A LeMaire; Tabitha Hendershot; Kim A Eagle; H Eser Tolunay; Patrice Desvigne-Nickens; Michael Silberbach Journal: Am J Med Genet A Date: 2013-02-26 Impact factor: 2.802
Authors: José M de la Torre-Hernández; Fernando Alfonso; Felipe Hernández; Jaime Elizaga; Marcelo Sanmartin; Eduardo Pinar; Iñigo Lozano; Jose M Vazquez; Javier Botas; Armando Perez de Prado; Jose M Hernández; Juan Sanchis; Juan M Ruiz Nodar; Alfredo Gomez-Jaume; Mariano Larman; Jose A Diarte; Javier Rodríguez-Collado; Jose R Rumoroso; Jose R Lopez-Minguez; Josepa Mauri Journal: J Am Coll Cardiol Date: 2008-03-11 Impact factor: 24.094
Authors: Stefan James; Dominick J Angiolillo; Jan H Cornel; David Erlinge; Steen Husted; Frederic Kontny; Juan Maya; Josë C Nicolau; Jindrich Spinar; Robert F Storey; Susanna R Stevens; Lars Wallentin Journal: Eur Heart J Date: 2010-08-29 Impact factor: 29.983
Authors: Nita A Limdi; Larisa H Cavallari; Craig R Lee; William B Hillegass; Ann M Holmes; Todd C Skaar; Maria Pisu; Chrisly Dillon; Amber L Beitelshees; Philip E Empey; Julio D Duarte; Vakaramoko Diaby; Yan Gong; Julie A Johnson; John Graves; Shawn Garbett; Zilu Zhou; Josh F Peterson Journal: Pharmacogenomics J Date: 2020-02-11 Impact factor: 3.550